Effect of Adriamycin Administered via Different Routes on Ehrlich Ascites Tumor Cells

Adriamycin (ADR) is an antineoplastic drug, isolated from Streptomyces peucetius var. caesius , and has cytotoxic features. It binds DNA by intercalation and inhibits replication and transcription. Clinically, ADR is used intravenously and intravesically. Ehrlich ascites tumor (EAT) was originated from breast carcinoma in a mouse. It grows in solid and ascitic forms. The aim of our study is to investigate the effectiveness of ADR on mice bearing EAT by comparing its administration routes. 0.01 mg.g -1 ADR was administered mice bearing EAT via intraperitoneal, intravenous and subcutaneous. On day 0 each mouse in the experiment was inoculated with 3x10 5 EAT cells. On the 2 nd , 4 th , 6 th , 8 th days after administration, number of viable cells and mitosis number were counted from each animal by drainage the ascites fluid from the peritoneal cavity of each mouse. Data were evaluated statistically. The most efficient in respect of curing properties was observed in group I in which ADR administered via intraperitoneal.